Meeting
2018 ASCO Annual Meeting
Circulating miR-371a-3p for the detection of low volume viable germ cell tumor: Expanded pilot data, clinical implications and future study.
Authors
Lucia Nappi
Vancouver Prostate Centre and SWOG AYA, Prevention and Surveillance and SWOG YI Award, Vancouver, BC, Canada
Lucia Nappi , Brock O Neil , Siamak Daneshmand , Robert James Hamilton , Ricardo Romao Nazario Leao , Marisa Thi , Kim N. Chi , Martin Gleave , Bernhard J. Eigl , Peter C. Black , Alan I. So , Daniel Khalaf , Christian K. Kollmannsberger , Craig R. Nichols
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Germ Cell/Testicular
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4549)
DOI
10.1200/JCO.2018.36.15_suppl.4549
Abstract #
4549
Poster Bd #
375
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Plasma miR371 for the detection of viable germ cell tumor in testicular cancer patients with enlarging or post chemotherapy residual nodes.
First Author: Lucia Nappi
Poster
2020 Genitourinary Cancers Symposium
Serum microRNA-371a-3p levels to predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.
First Author: Nirmish Singla
Poster
2015 Genitourinary Cancers Symposium
Risk-stratified treatment of patients with metastatic germ cell tumor with progression after first-line therapy.
First Author: Orvar Gunnarsson
Poster
2024 ASCO Annual Meeting
Management of relapsed stage I nonseminomatous germ-cell tumor with retroperitoneal only relapse.
First Author: Ahmed Bilal Khalid